According to a new report by Polaris Market Research, the global castrate-resistant prostate cancer (CRPC) market was valued at USD 12.92 billion in 2024 and is projected to reach USD 29.79 billion by 2034, expanding at a CAGR of 8.7% from 2025 to 2034. Growth is underpinned by rising prostate cancer incidence, an expanding geriatric population, and accelerating innovation in hormonal therapy, immunotherapy, and combination treatment regimens across key end-use markets.

What Is Driving Castrate-Resistant Prostate Cancer Market Growth?

Demand is climbing as rising rates of advanced prostate cancer diagnoses converge with an aging global population. Physicians and health systems are prioritizing combination therapies, such as pairing androgen receptor inhibitors with chemotherapy or immunotherapy, pushing CRPC treatment adoption across North America, Europe, and Asia Pacific. Polaris analysts note that increased funding for oncology research and accelerating regulatory approvals for novel drugs position the market for sustained growth through 2034, with hormonal therapy emerging as the largest revenue contributor and immunotherapy posting the fastest incremental gains.

Key Trends Shaping the Castrate-Resistant Prostate Cancer Industry

Rising Incidence of Prostate Cancer

The growing number of prostate cancer cases worldwide is driving more patients into castrate-resistant disease stages, intensifying demand for advanced treatment options. In the United States alone, the American Cancer Society projected roughly 299,010 new prostate cancer diagnoses in 2024, reinforcing the market outlook for CRPC-specific therapies as more patients transition to this advanced stage.

Growing Geriatric Population

An aging population is a critical driver of market growth, as a higher proportion of men entering the geriatric demographic correlates strongly with rising prostate cancer incidence. The World Health Organization projects that the global population aged 60 and above will grow from 1 billion in 2020 to 1.4 billion by 2030, intensifying demand for advanced CRPC treatment modalities and comprehensive management strategies.

Advances in Combination and Precision Therapies

Competitive landscape activity is increasingly centered on next-generation radioconjugates, targeted androgen receptor antagonists, and immune-based treatments. In June 2024, AstraZeneca completed its acquisition of Fusion Pharmaceuticals, adding the radioconjugate candidate FPI-2265 to its oncology pipeline and expanding its R&D capabilities in metastatic castration-resistant prostate cancer, a signal of the broader shift toward precision oncology reshaping the competitive landscape.

Market Segmentation: Breaking Down the Castrate-Resistant Prostate Cancer Market

Polaris segments the castrate-resistant prostate cancer market by therapy and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Therapy

The hormonal therapy segment held the largest market share in 2024, driven by the effectiveness of advanced hormonal therapies such as androgen receptor inhibitors (enzalutamide) and androgen biosynthesis inhibitors (abiraterone acetate) in managing disease progression and extending patient survival. The immunotherapy segment is expected to witness the highest CAGR through the forecast period, powered by cancer vaccines and immune checkpoint inhibitors that target cancer cells with high precision, rising investment in immunotherapy research, and growing demand for personalized medicine.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/castrate-resistant-prostate-cancer-market 

Regional Outlook: Where Is Castrate-Resistant Prostate Cancer Growing Fastest?

North America accounted for the largest market share in 2024 due to advanced healthcare infrastructure and high prostate cancer prevalence; the National Cancer Institute reported roughly 3.4 million men diagnosed with prostate cancer in the US in 2021 alone. Within the region, the United States leads on the strength of its concentration of major pharmaceutical companies and ongoing drug development innovation. Asia Pacific is expected to post the highest CAGR through 2034, driven by a growing geriatric population and rising cancer incidence, with China, Japan, and India reporting a combined 276,000-plus new prostate cancer cases in 2022 according to the World Cancer Research Fund. Japan's rapidly aging population and well-developed healthcare infrastructure are further accelerating adoption of advanced CRPC treatments in the region.

Competitive Landscape: Leading Castrate-Resistant Prostate Cancer Companies

Key players profiled in the report include Sanofi S.A., Johnson & Johnson, Pfizer, Inc., Bayer AG, and Astellas Pharma, Inc., who are focusing on R&D investment and expanding clinical trial portfolios to strengthen market position across the hormonal therapy and immunotherapy segments outlined above. Recent moves include AstraZeneca's June 2024 acquisition of Fusion Pharmaceuticals to bolster its radioconjugate oncology pipeline, and Sanofi's continued advancement of Jevtana (cabazitaxel) as a significant option in the prostate cancer treatment landscape, both aimed at deepening share in North America and Europe.

Why It Matters for Stakeholders Evaluating Market Entry

For stakeholders researching the castrate-resistant prostate cancer market, this report benchmarks market share, segment-level pricing, and forecast data — by therapy and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking immunotherapy as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Ready-to-Drink Cocktails Market

PTA Balloon Catheter Market

Glass Mat Market

Protein A, G, and L Resins Market

PTA Balloon Catheter Market

Automotive Tire Market

Equine Healthcare Market

Revolutionizing the Future: Unveiling the Mining Automation Market

Smart Pills Market